Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases

被引：11

作者：

Read, William L. ^{[1
]}

Williams, Felicia ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol Med Oncol, Atlanta, GA USA

来源：

CASE REPORTS IN ONCOLOGY | 2016年 / 9卷 / 03期

关键词：

Alveolar soft part sarcoma; Soft tissue sarcoma; Sunitinib; Pazopanib;

D O I：

10.1159/000450545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib, cediranib and bevacizumab. There is no established second-line treatment for persons with ASPS progressing through first-line targeted therapy. We report two individuals with metastatic ASPS who obtained disease stabilization from sunitinib lasting over a year. After subsequent progression through sunitinib and second-line bevacizumab, both individuals again had disease response and subsequent stabilization from pazopanib. (C) 2016 The Author(s) Published by S. Karger AG, Basel

引用

页码：639 / 643

页数：5

共 15 条

[1] Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report [J].

Bender, Julia L. Glade ;

Lee, Alice ;

Reid, Joel M. ;

Baruchel, Sylvain ;

Roberts, Timothy ;

Voss, Stephan D. ;

Wu, Bing ;

Ahern, Charlotte H. ;

Ingle, Ashish M. ;

Harris, Pamela ;

Weigel, Brenda J. ;

Blaney, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) :3034-U88

[2] Antiangiogenic Treatment as a Pre-Operative Management of Alveolar Soft-Part Sarcoma [J].

Conde, Nuria ;

Cruz, Ofelia ;

Albert, Asteria ;

Mora, Jaume .

PEDIATRIC BLOOD & CANCER, 2011, 57 (06) :1071-1073

[3] Bioinformatic Analysis of Patient-Derived ASPS Gene Expressions and ASPL-TFE3 Fusion Transcript Levels Identify Potential Therapeutic Targets [J].

Covell, David G. ;

Wallqvist, Anders ;

Kenney, Susan ;

Vistica, David T. .

PLOS ONE, 2012, 7 (11)

[4]

Dembla V, 2016, J CLIN ONCOL S, V34

[5] Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial [J].

Hainsworth, John D. ;

Rubin, Mark S. ;

Arrowsmith, Edward R. ;

Khatcheressian, James ;

Crane, Edward J. ;

Franco, Luis A. .

CLINICAL GENITOURINARY CANCER, 2013, 11 (03) :270-275

[6] Alveolar Soft Part Sarcoma [J].

Jaber, Omar I. ;

Kirby, Patricia A. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (11) :1459-1462

[7] Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072 [J].

Kasper, B. ;

Sleijfer, S. ;

Litiere, S. ;

Marreaud, S. ;

Verweij, J. ;

Hodge, R. A. ;

Bauer, S. ;

Kerst, J. M. ;

van der Graaf, W. T. A. .

ANNALS OF ONCOLOGY, 2014, 25 (03) :719-724

[8] Activity-based kinase profiling of approved tyrosine kinase inhibitors [J].

Kitagawa, Daisuke ;

Yokota, Koichi ;

Gouda, Masaki ;

Narumi, Yugo ;

Ohmoto, Hiroshi ;

Nishiwaki, Eiji ;

Akita, Kensaku ;

Kirii, Yasuyuki .

GENES TO CELLS, 2013, 18 (02) :110-122

[9] Cediranib for Metastatic Alveolar Soft Part Sarcoma [J].

Kummar, Shivaani ;

Allen, Deborah ;

Monks, Anne ;

Polley, Eric C. ;

Hose, Curtis D. ;

Ivy, S. Percy ;

Turkbey, Ismail B. ;

Lawrence, Scott ;

Kinders, Robert J. ;

Choyke, Peter ;

Simon, Richard ;

Steinberg, Seth M. ;

Doroshow, James H. ;

Helman, Lee .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18) :2296-U106

[10] Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma [J].

Mir, Olivier ;

Boudou-Rouquette, Pascaline ;

Larousserie, Frederique ;

Blanchet, Benoit ;

Babinet, Antoine ;

Anract, Philippe ;

Goldwasser, Francois .

ANTI-CANCER DRUGS, 2012, 23 (07) :745-748

← 1 2 →